IL12B and neoplasm: For EGFRmut LUAD patients (n = 47), low expression of IL12B (HR = 0.36, 95% CI = 0.137–0.947, and p = 0.0383 for the high vs. low IL12B expression EGFRmut subgroup; Fig. 5E) together with IL4 (HR = 0.382, 95% CI = 0.147–0.991, and p = 0.0479 for the high vs. low IL4 expression EGFRmut subgroup; Fig. 3B) were individually prognostic of a shorter RFS, increasing living risks before tumor recurrence by 2.78 and 2.62 times, respectively.